KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) EBT (2016 - 2025)

Amgen has reported EBT over the past 17 years, most recently at $1.5 billion for Q4 2025.

  • Quarterly results put EBT at $1.5 billion for Q4 2025, up 93.61% from a year ago — trailing twelve months through Dec 2025 was $9.0 billion (up 94.75% YoY), and the annual figure for FY2025 was $9.0 billion, up 94.75%.
  • EBT for Q4 2025 was $1.5 billion at Amgen, down from $3.9 billion in the prior quarter.
  • Over the last five years, EBT for AMGN hit a ceiling of $3.9 billion in Q3 2025 and a floor of -$68.0 million in Q1 2024.
  • Median EBT over the past 5 years was $1.7 billion (2022), compared with a mean of $1.8 billion.
  • Biggest five-year swings in EBT: plummeted 101.98% in 2024 and later skyrocketed 3001.47% in 2025.
  • Amgen's EBT stood at $2.1 billion in 2021, then decreased by 17.97% to $1.7 billion in 2022, then plummeted by 51.26% to $852.0 million in 2023, then dropped by 8.22% to $782.0 million in 2024, then skyrocketed by 93.61% to $1.5 billion in 2025.
  • The last three reported values for EBT were $1.5 billion (Q4 2025), $3.9 billion (Q3 2025), and $1.6 billion (Q2 2025) per Business Quant data.